Phase III dose-comparison study of glatiramer acetate for multiple sclerosis

Area of Science:

• Neuroscience
• Immunology
• Pharmacology

Background:

• Multiple Sclerosis (MS) is a chronic autoimmune disease affecting the central nervous system.
• Glatiramer acetate (GA) is an established immunomodulatory therapy for relapsing-remitting MS.
• Evaluating higher doses of GA may offer improved therapeutic outcomes.

Purpose of the Study:

• To compare the safety, tolerability, and efficacy of glatiramer acetate (GA) 40 mg versus 20 mg in patients with relapsing-remitting MS.
• To assess the impact of GA dosage on relapse rates and MRI lesion activity.

Main Methods:

• A randomized study involving 1,155 patients with relapsing-remitting MS.
• Patients received either GA 20 mg or 40 mg daily.
• Primary endpoint was the annualized relapse rate (ARR) over 12 months; secondary endpoints included MRI lesion changes.

Main Results:

• No significant difference in ARR between GA 20 mg (0.33) and 40 mg (0.35) groups (RR=1.07, p=0.486).
• 77% of patients remained relapse-free in both treatment arms.
• Both doses showed reductions in gadolinium-enhancing and new T2 lesions, with a trend for faster reduction with 40 mg GA in the first trimester.

Conclusions:

• Glatiramer acetate 20 mg and 40 mg are equally safe and well-tolerated in relapsing-remitting MS.
• The 40 mg dose of GA does not offer a significant efficacy advantage over the 20 mg dose in terms of relapse reduction.
• Both doses effectively reduce MS disease activity as evidenced by MRI.